on MIG CAPITAL AG
MIG Capital Reports Strategic Investments and Positive 2024 Results
In 2024, MIG Capital, a significant venture capital firm in Germany, successfully navigated a challenging market by investing €41 million in ground-breaking deep tech and life sciences start-ups. Despite Germany's economic downturn, the firm facilitated €232 million in fresh capital to its portfolio companies in collaboration with co-investors.
New additions to MIG's portfolio include HawkCell, a healthcare start-up, GlassPoint in the cleantech sector, and autoimmune biotech, SciRhom. These strategic investments underscore the firm's commitment to innovation in sectors poised for advancement.
In 2025, MIG Capital plans to continue focusing on innovative start-ups and profitable exits. The investment strategy benefits from the solid expertise of professionals like Christina Vogt-Sasse, who joined the team in 2024, bolstering its focus on European deep tech ventures.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MIG CAPITAL AG news